DOCSLIB.ORG

Combination Effect of Antitumor Agents, Including Doxorubicin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination Effect of Antitumor Agents, Including Doxorubicin [Gann, 68, 459～464; August, 1977] INTERACTION OF ANTITUMOR AGENTS INCLUDING DOXORUBICIN OR DAUNORUBICIN IN SARCOMA-180 SYSTEM Masaaki IIGO, Fumihiko KANZAWA, Asako NAKAMURA, Akio HOSHI, and Kazuo KURETANI Pharmacology Division, National Cancer Center Research Institute* Combination effect of antitumor agents, including doxorubicin and dauno- rubicin, was evaluated on the concept of pharmacological synergism in ascites sarcoma-180 system. In alternate administration, combinations of doxorubicin plus cyclophosphamide, thio-TEPA, carboquone, actinomycin-D, vinblastine, vincristine, methotrexate, cytarabine, 6-mercaptopurine, or L-asparaginase show- ed synergism, but in simultaneous one, only three agents, cyclophosphamide, carboquone, and cytarabine, were synergistic. On the other hand, combination of daunorubicin plus one of 8 agents (thio-TEPA, mitomycin-C, bleomycin, actinomycin-D, vinblastine, ancytabine, 6-mercaptopurine, and L-asparaginase) and 6 agents (cyclophosphamide, thio-TEPA, mitomycin-C, bleomycin, actino- mycin-D, and vinblastine) provided synergism in alternate and simultaneous administration. Combination effect of agents was affected by the schedule of drug administration for doxorubicin, but weak for daunorubicin. Toxicity of doxorubicin or daunorubicin in combination with other drugs was also affected by the schedule of administration. Combination of a larger number of agents in simultaneous administration provided antagonism compared with an alternate administration. Combination chemotherapy provides a the L-1210 system, we developed a reason- clinical advantage over single-drug treat- ably quantitative method for examining the ment.5,13) As the number of new drugs in- activity and toxicity of a combination of creases yearly, the number of possible com- agents separately.7,9,10) By the extension of binations also increases. The most appropriate these studies, interaction of antitumor agents, combination of agents and treatment schedule including daunorubicin and doxorubicin, in must be selected among numerous possible activity against sarcoma-180 and lethal toxi- candidates. Up to the present, most of the city to the host animals, and of schedule of combination therapy in animal models was administration on the interaction of anti- examined with the L-1210 leukemia system14) tumor agents were examined. and the results were evaluated by the "ther- apeutic synergism" and not by pharmacol- MATERIALS AND METHODS ogical synergism. By the former method, Animals and Tumor System Female ddN antitumor activity and toxicity to the host mice weighing 20 ± 2g were used , and 0.05ml animals cannot be evaluated separately, and (1 × 107 cells) of 7-day-old ascites sarcoma-180 the method cannot be applied to other tumor was inoculated intraperitoneally to six mice in systems in which antitumor activity is eval- one group.6) Antitumor Agents As shown in Table I, 16 uated by the inhibition of tumor growth. antitumor agents were used. Cyclophosphamide In order to determine the combination effect (Endoxan; Shionogi & Co., Osaka), thio-TEPA of antitumor agents in systems other than (Tespamine; Sumitomo Chemical Industries, * Tsukiji 5-1-1 , Chuo-ku, Tokyo 104(飯 郷 正 明,官 沢 文 彦,中 村 朝 子,星 昭 夫,榑 谷 和 男) . 68(4) 1977 459 M. IIGO, ET AL. Table I. Activity against Sarcoma-180 Ascites be combined with A as listed in Table I. The and Toxicity to Mice of Antitumor antitumor activity was evaluated by the total Agents packed cell volume ratio on, the 7th day after tumor inoculation in the sarcoma-180 system as reported previously.6) Evaluation of Drug Toxicity LD50 of the agents in normal ddN mice was calculated by daily injection for 5 days and survivors on 14th day after the first injection by the method of Litchfield-Wilcoxon.12) Doses of two compounds (A and B) in combination were one-half of LD50 of A plus one-half of LD50 of B per day for simul- taneous administration, and LD50 of A on 1st, 3rd, and 5th day and LD50 of B on 2nd and 4th day for alternate administration, where A means doxorubicin or daunorubicin and B means one of the rest of compounds. Evaluation of Drug Interaction The terms synergism, antagonism, and additive action were used according to the definition given by Wells.15) For a combination of two drugs (A and B), if equally effective doses (a and b) of A and B are combined, it holds true that: Effect of dose a = Effect of dose b Effect(1/2 dose a + 1/2 dose b) =q(simul- Effect of dose a taneous) Effect(alternate(doseand a dose b)=q(alter- Effect of dose a Osaka), mitomycin-C (Mitomycin Kyowa-S; Kyo- nate) wa Hakko Co., Tokyo), daunorubicin (Dauno- If q = 1, there is additivity in the action of the mycin; Meiji Seika Kaisha, Tokyo), bleomycin drugs combined. If q>1, there is a synergism in (Bleo; Nippon Kayaku Co., Tokyo), actinomycin- action. If q<1, there is an antagonism in action.2) D (Cosmegen; Nippon Merck-Banyu Co., Tokyo), Interaction of agents is defined as synergism for vinblastine (Exal; Shionogi & Co.), vincristine 0～20, additive action for 21～80, and antagonism (Oncovin; Shionogi & Co.), methotrexate (Takeda for 80～100 of T/C% in tumor growth. Interaction Chemical Industries, Osaka), 6-mercaptopurine of agents for toxicity is defined as synergism for (Sigma, U. S.A.), and L-asparaginase (Leunase; 5～6, additive for 2～4, and antagonism for 0～1 Kyowa Hakko Kogyo Co.) were purchased com- dead animals out of six mice. mercially. Carboquone (carbazilquinone) was kindly supplied by Sankyo Co., Tokyo, doxorubi- cin (KW-125) and 5-fluorouracil by Kyowa Hakko RESULTS Kogyo Co., and ancytabine (cyclocytidine) and Interaction in Antitumor Activity of cytarabine (cytosine arabinoside) by Kohjin Co., Agents Administered Simultaneously Tokyo. ED50 (dosage showing 50% inhibition in tumor growth) and LD50 (dosage showing 50% In combination chemotherapy, the basic lethality in treated animals) of the agents in combination is a pair of drugs and the sched- normal ddN mice are also shown in Table I. ule of administration of agents calls for two Evaluation of Antitumor Activity Test com- procedures, simultaneous and sequential ad- pounds were injected intraperitoneally once daily ministration. Therefore, interaction between for 5 days, starting 24hr after tumor inoculation. The doses of two compounds (A and B) were two drugs administered simultaneously was one-half of ED50 of A plus one-half of ED50 of B first examined. As shown in Fig. 1, three per day for simultaneous administration or ED50 compounds (cyclophosphamide, carboquone, of A on 1st, 3rd, and 5th day and ED50 of B on and cytarabine) combined with doxorubicin 2nd and 4th day for alternate administration, where A means doxorubicin or daunorubicin and showed synergism, no compound showed B means one of the remaining 15 compounds to antagonism, and the rest of 12 compounds 460 Gann EFFECT OF COMBINATION OF ANTITUMOR AGENTS Fig. 1. Effect of doxorubicin and daunorubicin in combination with other agents in simultane- ous administration showed an additive action, when adminis- istration on the activity was marked in this tered in equally effective dosages in the sar- case. The combinations showing synergism coma 180 system. On the other hand, when in activity were more numerous in alternate combined with daunorubicin, cyclophospha- administration than in simultaneous one. On mide, thio-TEPA, mitomycin-C, bleomycin, the other hand, eight combinations containing actinomycin-D, and vinblastine showed syner- daunorubicin were synergistic, that is, thic- gism and no compound showed antagonism. TEPA, mitomycin-C, bleomycin, actinomy- The rest of 9 combinations showed an additive cin-D, vinblastine; ancytabine, 6-mercapto- action. purine, or L-asparaginase plus daunorubicin. Interaction of Agents Administered Al- Influence of the schedule of administration ternately on Antitumor Activity Influ- on the activity was weak in this case (Fig . 2). ence of the schedule of administration on Interaction in Lethal Toxicity of Anti- antitumor activity was also examined. One tumor Agents Interaction in toxicity of of the sequential administrations was con- the agents was examined. In simultaneous sidered to be the alternate administration. administration, 1 (carboquone), 5 (mitomy- In this case, two agents were considered not cin-C, vincristine, methotrexate , 5-fluoroura- to exist in tissues at the same time. Ten cil, and 6-mercaptopurine), and 8 compounds compounds (cyclophosphamide, thio-TEPA, combined with doxorubicin showed syner- carboquone, actinomycin-D, vinblastine, vin- gism, antagonism, and additive action, re- cristine, methotrexate, cytarabine, 6-mercap- spectively (Fig. 3). In combinations contain- topurine, and L-asparaginase) showed syner- ing daunorubicin, 2 (bleomycin and cytara - gism in combination with doxorubicin. The bine), 7 (thio-TEPA , carboquone, mitomy- rest of 5 compounds showed an additive cin-C, actinomycin-D , ancytabine, 5-fluoro- action. Influence of the schedule of admin- uracil, and 6-mercaptopurine) , and 5 com- 68(4) 1977 461 M. IIGO, ET AL. Fig. 2. Effect of doxorubicin and daunorubicin in combination with other agents in alternate administration Fig. 3. Toxicity of doxorubicin and daunorubicin in combination with other agents in simul- taneous administration 462 Gann EFFECT OF COMBINATION OF ANTITUMOR AGENTS Fig. 4. Toxicity of doxorubicin and daunorubicin in combination with other agents in alternate administration pounds showed synergism, antagonism, and quone and daunorubicin plus bleomycin in additive action, respectively (Fig. 3). Com- simultaneous
Load more

Recommended publications
  • Treatment of Localized Extranodal NK/T Cell Lymphoma, Nasal Type: a Systematic Review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim*
    Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Open Access Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim* Abstract Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non- anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL. Keywords: Extranodal NK/T cell lymphoma, Chemoradiotherapy, Localized disease Background Treatment for newly diagnosed patients with localized Extranodal natural killer/T cell lymphoma (ENKTL), nasal nasal ENKTL type, is a rare subtype of non-Hodgkin lymphoma [1].
    [Show full text]
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, Firas El Chaer 4, James A
    Journal of Clinical Medicine Article Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Ciera L. Patzke 1, Alison P. Duffy 1,2, Vu H. Duong 1,3, Firas El Chaer 4, James A. Trovato 2, Maria R. Baer 1,3, Søren M. Bentzen 1,3 and Ashkan Emadi 1,3,* 1 Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; [email protected] (C.L.P.); aduff[email protected] (A.P.D.); [email protected] (V.H.D.); [email protected] (M.R.B.); [email protected] (S.M.B.) 2 School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA; [email protected] 3 School of Medicine, University of Maryland, Baltimore, MD 21201, USA 4 School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-328-2596 Received: 10 January 2020; Accepted: 13 February 2020; Published: 16 February 2020 Abstract: Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027).
    [Show full text]
  • A Comparison of Early Intensive Methotrexate/Mercaptopurine With
    Leukemia (2001) 15, 1038–1045 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial SJ Lauer1, JJ Shuster2, DH Mahoney Jr3, N Winick4, S Toledano5, L Munoz5, G Kiefer6, JD Pullen7, CP Steuber3 and BM Camitta6 1Emory University School of Medicine, Atlanta, GA; 2Pediatric Oncology Group Statistical Office and Department of Statistics, University of Florida, Gainesville, FL; 3Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX; 4University of Texas Southwestern Medical Center, Dallas, TX; 5University Miami School of Medicine, Miami, FL; 6Midwest Children’s Cancer Center, Milwaukee, WI; and 7University of Mississippi Medical Center Children’s Hospital, Jackson, MS, USA A prospective, randomized multicenter study was performed to to their risk for relapse and treatment strategies designed to evaluate the relative efficacy of two different concepts for early improve event-free survival (EFS). intensive therapy in a randomized trial of children with B-pre- cursor acute lymphoblastic leukemia (ALL) at high risk (HR) for It is believed that the leading causes of relapse in children relapse. Four hundred and ninety eligible children with HR-ALL with higher risk ALL (HR-ALL) are inadequate cell kill and were randomized on the Pediatric Oncology Group (POG) 9006 emergence of drug-resistant clones. Clinical trials using early phase III trial between 7 January 1991 and 12 January 1994. intensive myelosuppressive combination chemotherapy as After prednisone (PDN), vincristine (VCR), asparaginase (ASP) post-induction consolidation were designed to maximize cell and daunorubicin (DNR) induction, 470 patients received either 2 kill and address drug resistance.
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • Incidence of Differentiation Syndrome Associated with Treatment
    Journal of Clinical Medicine Review Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature Lucia Gasparovic 1, Stefan Weiler 1,2, Lukas Higi 1 and Andrea M. Burden 1,* 1 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland; [email protected] (L.G.); [email protected] (S.W.); [email protected] (L.H.) 2 National Poisons Information Centre, Tox Info Suisse, Associated Institute of the University of Zurich, 8032 Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41-76-685-22-56 Received: 30 August 2020; Accepted: 14 October 2020; Published: 18 October 2020 Abstract: Differentiation syndrome (DS) is a potentially fatal adverse drug reaction caused by the so-called differentiating agents such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), used for remission induction in the treatment of the M3 subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL). However, recent DS reports in trials of isocitrate dehydrogenase (IDH)-inhibitor drugs in patients with IDH-mutated AML have raised concerns. Given the limited knowledge of the incidence of DS with differentiating agents, we conducted a systematic literature review of clinical trials with reports of DS to provide a comprehensive overview of the medications associated with DS. In particular, we focused on the incidence of DS reported among the IDH-inhibitors, compared to existing ATRA and ATO therapies. We identified 44 published articles, encompassing 39 clinical trials, including 6949 patients. Overall, the cumulative incidence of DS across all treatment regimens was 17.7%.
    [Show full text]
  • Daunorubicin Hydrochloride Injection Hikma Pharmaceuticals USA Inc
    DAUNORUBICIN HYDROCHLORIDE- daunorubicin hydrochloride injection Hikma Pharmaceuticals USA Inc. ---------- DAUNORUBICIN HYDROCHLORIDE INJECTION Rx ONLY WARNINGS 1.Daunorubicin Hydrochloride Injection must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration. 2.Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m2 in adults, 300 mg/m2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age. 3.Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage. 4.It is recommended that daunorubicin hydrochloride be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5.Dosage should be reduced in patients with impaired hepatic or renal function. DESCRIPTION Daunorubicin hydrochloride is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of Streptomyces coeruleorubidus. It is provided as a deep red sterile liquid in vials for intravenous administration only. Each mL contains 5 mg daunorubicin (equivalent to 5.34 mg of daunorubicin hydrochloride), 9 mg sodium chloride; sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection, q.s.
    [Show full text]
  • HYDREA Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr HYDREA® Hydroxyurea Capsules, 500 mg USP Antineoplastic Agent Bristol-Myers Squibb Canada Date of Initial Authorization: Montreal, Canada MAR 23, 1979 Date of Revision: AUGUST 10, 2021 Submission Control Number: 250623 HYDREA® (hydroxyurea) Page 1 of 26 RECENT MAJOR LABEL CHANGES 1 Indications 02/2020 7 Warnings and Precautions, Hematologic 08/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................... 22 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................
    [Show full text]
  • Benefit of Intermediate-Dose Cytarabine-Containing Induction In
    Letters to the Editor ter RFS and EFS rates and showed a marked tendency to Benefit of intermediate-dose cytarabine-containing improve the OS of patients with CEBPAdm in both uni- induction in molecular subgroups of acute myeloid variate and multivariable analyses, as shown in Online leukemia Supplementary Table S2. Five-year RFS, EFS, and OS rates were 85%, 81%, and 88% in the intermediate-dose com- The outcome of acute myeloid leukemia (AML) is pared with 56%, 56%, and 68% in the conventional- affected by disease characteristics as well as treatment dose group, respectively (Figure 1). In total, 13 of 75 1-3 regimens. In the CALGB8525 trial, patients with core (17%) patients with CEBPAdm AML underwent allo- binding factor (CBF)-positive leukemia benefited from geneic transplantation in CR1, including five of 32 (16%) 4 consolidation with a high dose of cytarabine. More in the conventional-dose group and eight of 43 (19%) in 2 recently, high-dose daunorubicin (60-90 mg/m ) has the intermediate-dose group. To analyze results in the 5,6 become widely used. High-dose daunorubicin confers a absence of any possible contributory effect of transplan- favorable prognosis for patients with NPM1 muta- tation, patients were censored at the time of transplanta- 1,7,8 tions. tion in CR1. Patients with CEBPAdm AML exposed to Higher-dose cytarabine was also introduced into AML intermediate-dose cytarabine achieved an increase in 5- 3,9 induction therapy. Recently, we investigated the role of year RFS, censored at the date of transplantation, from intermediate-dose cytarabine in induction therapy of 56% to 83% (hazard ratio [HR], 0.313; 95% confidence AML and found that the introduction of intermediate- interval [95% CI]: 0.119-0.824; Wald P=0.019) (Online dose cytarabine, combined with daunorubicin and omac- Supplementary Figure S3).
    [Show full text]
  • Asparaginase As Consolidation Therapy in Patients Undergoing Bone Marrow Transplantation for Acute Lymphoblastic Leukemia
    Bone Marrow Transplantation, (1998) 21, 879–885 1998 Stockton Press All rights reserved 0268–3369/98 $12.00 http://www.stockton-press.co.uk/bmt Toxicity, pharmacology and feasibility of administration of PEG-L- asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia ML Graham1, BL Asselin2, JE Herndon II3, JR Casey1, S Chaffee1, GH Ciocci1, CW Daeschner4, AR Davis4, S Gold6, EC Halperin7, MJ Laughlin1, PL Martin8, JF Olson1 and J Kurtzberg1,9 Departments of 1Pediatrics, 3Community and Family Medicine, 5Pharmacy, 7Radiation Oncology and 9Pathology, Duke University Medical Center, Durham, NC; 2Department of Pediatrics, University of Rochester, Rochester, NY; 4Department of Pediatrics, Eastern Carolina University School of Medicine, Greenville; 6Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill; 8Department of Pediatrics, Bowman-Gray School of Medicine, Winston-Salem, NC, USA Summary: for bone marrow transplantation have occasionally been successful, but usually at the price of higher morbidity and We attempted to administer PEG-L-asparaginase (PEG- mortality rates, since most preparative regimens employ L-A) following hematologic recovery to 38 patients maximal or near maximal radiation and chemotherapy undergoing autologous or allogeneic marrow transplan- doses.6–8 tation for acute lymphoblastic leukemia (ALL). Twenty- Other strategies for reducing relapse have been explored. four patients (12 of 22 receiving allogeneic and 12 of 16 Since the development of graft-versus-host disease receiving autologous transplants) received between one (GVHD) in some series of allogeneic BMT has been asso- and 12 doses of PEG-L-A, including nine who com- ciated with a diminished relapse rate,9–12 Sullivan et al13 pleted the planned 12 doses of therapy.
    [Show full text]
  • Prescribing Information | VELCADE® (Bortezomib)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Hypotension: Use caution when treating patients taking These highlights do not include all the information needed to antihypertensives, with a history of syncope, or with dehydration. use VELCADE safely and effectively. See full prescribing (5.2) information for VELCADE. Cardiac Toxicity: Worsening of and development of cardiac VELCADE® (bortezomib) for injection, for subcutaneous or failure has occurred. Closely monitor patients with existing heart intravenous use disease or risk factors for heart disease. (5.3) Initial U.S. Approval: 2003 Pulmonary Toxicity: Acute respiratory syndromes have ------------------------RECENT MAJOR CHANGES-------------------------- occurred. Monitor closely for new or worsening symptoms and consider interrupting VELCADE therapy. (5.4) Warnings and Precautions, Posterior Reversible Encephalopathy Syndrome: Consider MRI Thrombotic Microangiopathy (5.10) 04/2019 imaging for onset of visual or neurological symptoms; ------------------------INDICATIONS AND USAGE-------------------------- discontinue VELCADE if suspected. (5.5) VELCADE is a proteasome inhibitor indicated for: Gastrointestinal Toxicity: Nausea, diarrhea, constipation, and treatment of adult patients with multiple myeloma (1.1) vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement. (5.6) treatment of adult patients with mantle cell lymphoma (1.2) Thrombocytopenia and Neutropenia: Monitor complete blood ----------------------DOSAGE AND ADMINISTRATION---------------------
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]